Computer-assisted selective optimization of side-activities

webinar

Thu, 06 Jun 2019, 16:00 CEST (Berlin)

Julius Pollinger and Simone Schierle, Goethe University Frankfurt, Germany

Computer-assisted selective optimization of side-activities

The discovery of bioactive small molecules is an expensive and time consuming yet central task in drug discovery. A potentially superior way to identify new drug candidates is the selective optimization of side activities (SOSA), which employs known drugs for their side-activities as lead compounds, while diminishing their original activity. Virtually every small molecule drug interacts with more than one molecular target and, thus, has side-activities.

We have observed such side-activity for the cysteinyl leukotriene receptor 1 (CysLT1R) antagonist cinalukast on the nuclear peroxisome proliferator-activated receptor α (PPARα). We chose this synthetically challenging experimental drug to study whether the application of well-established computational optimization and ranking methods can help identify the most promising variations for SOSA and reduce the synthetic efforts needed in this lead optimization concept. We employed SeeSAR to visualize the critical parts for supportive or undesirable interactions with the nuclear receptor. In a proof-of-concept study, we confirmed the suitability of the HYDE ranking for the task of compound prioritization concerning potency on PPARα and screened an automatically generated virtual library of approximately 8000 close cinalukast analogues using a self-designed KNIME® workflow with FlexX and HYDE. The top-ranking molecules from this first aspect of SOSA were then computationally studied for CysLT1R antagonism using a random forest model trained on fingerprint representations of known CysLT1R antagonists. A computationally favoured cinalukast analogue was synthesized and its in vitro profiling confirmed the predicted activity shift towards higher activation efficacy on PPARα and markedly improved selectivity over CysLT1R compared to the lead compound.

Current news

category
Events
Upcoming Lunch Workshops in San Diego & San Francisco
July 4, 2025 16:30 CEST
Why not make good use of an extended lunch break for a change? Join the BioSolveIT team for two informal lunch events in San Diego and San Francisco, featuring a short workshop on efficient strategies for exploring chemical space and processing large molecular datasets — key topics in early-stage drug...
Read on
category
Events
Announcing BioSolveIT's DrugSpace Symposium 2025: Bridging Science
June 26, 2025 09:43 CEST
We are pleased to announce the fourth edition of the BioSolveIT DrugSpace Symposium, taking place on September 24–25, 2025. This year’s theme, “Bridging Science,” highlights the growing importance of interdisciplinary collaboration in driving innovation across the drug discovery landscape. As the field evolves, it becomes increasingly clear that real progress...
Read on
Psst... Are You Following Us Yet? Follow the Science (and a Bit More)
June 25, 2025 08:44 CEST
There’s a lot going on behind the scenes—ideas taking shape, tools evolving, science in motion. And while the website tells you what our software does, our social media gives you a look at how it lives. We’re active on LinkedIn, BlueSky, and YouTube, sharing everything from scientific snapshots to educational...
Read on